News headlines about Covance (NYSE:CVD) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Covance earned a news impact score of 0.20 on Accern’s scale. Accern also gave media stories about the healthcare company an impact score of 46.4002588547421 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Covance (CVD) opened at $107.07 on Wednesday.
TRADEMARK VIOLATION WARNING: This report was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/15/covance-cvd-receiving-somewhat-favorable-press-coverage-report-shows.html.
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.